Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours
4 affiliations
- 1Department of Pediatrics University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
- 2Department of Medical Sciences University of Wisconsin School of Veterinary Medicine Madison Wisconsin USA
- 3Carbone Cancer Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
- 4Department of Pediatrics University of Minnesota Minneapolis Minnesota USA
Abstract
Companion canines need advances in therapeutic options for solid tumour malignancies. Natural killer (NK) cell infusions offer a promising treatment modality in canines with solid tumours. Autologous natural killer products are limited by dysfunctional immunity and a manufacturing process that delays care whereas allogeneic NK cells offer the possibility of ‘off‐the‐shelf’ therapy to be administered from healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy canine donors via density gradient separation. NK cells were expanded with recombinant human IL‐2 and canine IL‐21 with the addition of K562 feeder cells transfected with CD137 ligand and membrane bound human IL‐15. Additional experiments included IL‐12 during expansion. In vitro potency was assessed via co‐culture with the D17‐mKate2 canine osteosarcoma cell line. Three canines were enrolled in a phase 1 trial infusing ex vivo expanded allogeneic NK cells after lymphodepletion. Flow cytometric analysis confirmed successful expansion of canine NK cells with up to 50% of cells demonstrating NKp46+ after 14 days. Residual T cell numbers varied based on donor. The addition of IL‐12 led to increased NK cell expansion. Incucyte demonstrated potency with increasing osteosarcoma cell death at higher effector to target ratios. Three canines with metastatic/refractory solid tumours were successfully lymphodepleted and infused with allogeneic NK cell products. The canines tolerated the infusions well. Canine allogeneic NK cells were successfully expanded and activated ex vivo, demonstrated potency in vitro and safety in vivo. Further studies will optimise the NK cell product and escalate dosing to reach the maximal tolerable dose.
Related
- Real-world feasibility of first-line palbociclib for hormone receptor-positive HER2-negative locally advanced/metastatic breast cancer in women aged 70 years and older – final results of the endocrine-sensitive cohort in the French prospective non-interventional PalomAGE study
- Comparative prognostic analysis of allogeneic hematopoietic stem cell transplantation regimens in the treatment of severe aplastic anemia
- Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
- F-OGS, a new “Follow-up Onco-Geriatric Screening” tool during the follow-up of older patients undergoing oncological treatment. Pilot study of feasibility and acceptability
- Which quality of life issues are important to patients with metastatic breast cancer: Phase 1 and 2 development of European Organisation for Research and Treatment of Cancer metastatic breast cancer module (EORTC QLQ-MBR)
BibTeX
@article{weisnicht2026safety,
title = {{Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours}},
author = {Allison M. Weisnicht and Fernanda Szewc and Monica Moonkyung Cho and Han‐Yun Hannah Cheng and Swetha Ganesh and Lauren Mahoney and Kathryn Fox and Portia R. Smith and Mallery Olsen and Rebecca M. Richards and David M. Vail and Christian M. Capitini},
journal = {Veterinary and Comparative Oncology},
year = {2026},
month = jul,
doi = {10.1111/vco.70091},
url = {https://doi.org/10.1111/vco.70091},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours
AU - Allison M. Weisnicht
AU - Fernanda Szewc
AU - Monica Moonkyung Cho
AU - Han‐Yun Hannah Cheng
AU - Swetha Ganesh
AU - Lauren Mahoney
AU - Kathryn Fox
AU - Portia R. Smith
AU - Mallery Olsen
AU - Rebecca M. Richards
AU - David M. Vail
AU - Christian M. Capitini
PY - 2026
DA - 2026/07/16
JO - Veterinary and Comparative Oncology
DO - 10.1111/vco.70091
UR - https://doi.org/10.1111/vco.70091
AB - Companion canines need advances in therapeutic options for solid tumour malignancies. Natural killer (NK) cell infusions offer a promising treatment modality in canines with solid tumours. Autologous natural killer products are limited by dysfunctional immunity and a manufacturing process that delays care whereas allogeneic NK cells offer the possibility of ‘off‐the‐shelf’ therapy to be administered from healthy donors. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy canine donors via density gradient separation. NK cells were expanded with recombinant human IL‐2 and canine IL‐21 with the addition of K562 feeder cells transfected with CD137 ligand and membrane bound human IL‐15. Additional experiments included IL‐12 during expansion. In vitro potency was assessed via co‐culture with the D17‐mKate2 canine osteosarcoma cell line. Three canines were enrolled in a phase 1 trial infusing ex vivo expanded allogeneic NK cells after lymphodepletion. Flow cytometric analysis confirmed successful expansion of canine NK cells with up to 50% of cells demonstrating NKp46+ after 14 days. Residual T cell numbers varied based on donor. The addition of IL‐12 led to increased NK cell expansion. Incucyte demonstrated potency with increasing osteosarcoma cell death at higher effector to target ratios. Three canines with metastatic/refractory solid tumours were successfully lymphodepleted and infused with allogeneic NK cell products. The canines tolerated the infusions well. Canine allogeneic NK cells were successfully expanded and activated ex vivo, demonstrated potency in vitro and safety in vivo. Further studies will optimise the NK cell product and escalate dosing to reach the maximal tolerable dose.
SN - 1476-5810
SN - 1476-5829
ER -